Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos,Eftathios Kastritis,Evdoxia Hatjiharissi,Eirini Katodritou,Evangelos Eleutherakis-Papaiakovou,Evgenia Verrou,Maria Gavriatopoulou,Alexandros Leonidakis,Ioannis Ntanasis-Stathopoulos,Sosana Delimpasi,Marie-Christine Kyrtsonis,Maria Papaioannou,Argiris Symeonidis,Meletios A Dimopoulos

doi:10.1182/blood-2019-124638

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, Eftathios Kastritis + Show 12 more

Open Access

https://doi.org/10.1182/blood-2019-124638

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 2

Affiliation: National and Kapodistrian University of Athens, Aristotle University of Thessaloniki, Theageneio General Hospital, Datamed Systems Integration (Greece), Evangelismos Hospital, University of Patras

#CTX Levels #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Full Text